- Satellos Bioscience (MSCL) has closed a public offering of units raising gross proceeds of $3,500,000
- The company issued 8,750,000 units for $0.40 per unit
- The net proceeds will be used to advance the discovery and development of a small molecule drug for the treatment of Duchenne muscular dystrophy
- Satellos is dedicated to developing therapeutics that stimulate or restore muscle regeneration in severe disorders
- Satellos Bioscience (MSCL) is down 1.33 per cent on the day, trading at C$0.37 per share at 11 am ET
Satellos Bioscience (MSCL) has closed a public offering of units raising gross proceeds of $3,500,000.
The company issued 8,750,000 units for $0.40 per unit. Each unit consists of one common share and one-half of one share purchase warrant. Each whole warrant is exercisable for one additional share at $0.60 until September 13, 2025.
The net proceeds will be used to advance the discovery and development of a small molecule drug for the treatment of Duchenne muscular dystrophy and characterization activities intended to identify a development candidate by the end of 2022.
Satellos is dedicated to developing therapeutics that stimulate or restore muscle regeneration in severe disorders.
Satellos Bioscience (MSCL) is down 1.33 per cent on the day, trading at C$0.37 per share at 11 am ET.
